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Abstract
Reliable mouse models are key in the discovery and development of novel anticancer treatments. Non-invasive
monitoring techniques such as bioluminescence imaging (BLI) are useful tools to determine tumor engraftment
and evaluate tumor growth. However, the development of ascites in ovarian cancer mouse models leads to
possible difficulties. Ascites can interfere with the set-up of correct end points and can interfere with the
evaluation of tumor volume using BLI. We provide optimized euthanasia criteria and in vivo data underlining
the pitfalls of BLI.
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Background
With great interest, we read the article of Liao et al.
entitled “Preservation of tumor-host immune interac-
tions with luciferase-tagged imaging in a murine
model of ovarian cancer” [1] in the Journal for Im-
munoTherapy of Cancer. Adequate mouse models are
paramount for translational cancer research. With the
development of immunotherapy in the field of anti-
cancer treatment, we should turn to immune compe-
tent syngeneic models such as the ID8-Luc2 model
described by Liao et al.
Estimating and monitoring tumor load in ovarian
cancer is challenging. With innumerable peritoneal
implants that are formed, we rely in a clinical setting
on CT (computed tomography) or MRI (magnetic
resonance imaging) to evaluate tumor growth and dis-
ease progression, based on the RECIST 1.1 criteria
[2]. The RECIST criteria use target lesions as surro-
gate measure for tumor load, as total tumor load can-
not be quantified in a clinical setting. In animal models,
bioluminescence imaging (BLI) is a well-established
technique that allows non-invasive quantification of tumor
load [3]. Typically, stably integrating retroviral vectors are
used to generate stable luciferase expressing reporter lines,
that are applied to the respective animal models to monitor
tumor growth: cells that express the firefly reporter enzyme
generate a photon flux (light) when luciferin (the luciferase
substrate) is oxidized in the presence of ATP. As a conse-
quence, only live tumor cells that express the enzyme can
be monitored by detecting the emitted photons, rendering
BLI an excellent and sensitive tool to examine tumor
growth in mouse models, as was demonstrated nicely by
the authors.
Using BLI, we could even demonstrate established
tumor growth after as little as one week after inocula-
tion (minimum 10 x 106 ID8-fLuc cells), long before
macroscopic tumor or weight increase is detected.
For further reference we will refer to the experiments
performed by our research group with Firefly lucifer-
ase (luc1) transduced ID8 cell line as ID8-fLuc in
contrast to ID8-Luc2 described by Liao et al. How-
ever, according to us, the technique also comes with
significant shortcomings: is the photon flux a reliable
measure for tumor volume after the onset of ascites
(Fig. 1)? Luciferase activity is proportional to the
number of cells that express the reporter, as long as
the substrate luciferin is in abundance, and as long as
ATP is available. For BLI we administer 126 mg/kg of
luciferin in a concentration of 15 mg/L intraperitoneal
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(ip) to the mice [4]. However, in a mouse with asci-
tes, the luciferin will be diluted in up to 15 mL of as-
cites, which consequently results in suboptimal
substrate concentrations and accompanying photon
flux and thus an underestimation of tumor load.
When we inoculated mice with 15 × 106 ID8-fLuc
cells ip the mice developed clinically appreciable asci-
tes 6 weeks after inoculation, in contrast to the group
inoculated with 10 × 106 ID8-fLuc cells, which devel-
oped ascites 8 weeks after tumor engraftment (Fig. 2a).
Using a pieceweise multilevel model, we were able to
show a significant difference in the BLI curves of the
10 × 106 compared with the 15 × 106 group until the
6th week. To underscore that this stagnation of the
BLI signal 6 weeks after inoculation in the 15 × 106
ID8-fLuc group is linked to the presence of ascites
we scanned mice with ascites before and after drain-
age of ascites.
Figure 2c shows significant increase in BLI signal
after drainage of ascites. Therefore, we conclude that
the occurrence of ascites affects the BLI photon flux
and hence these measurements do not recapitulate
the tumor growth. Especially if these mice receive
treatments that can affect the development of ascites
this is of particular importance. Moreover, in large
tumor volumes the photon flux is mostly also an
underestimate of tumor load, due to internal necrosis
or weak vascularization of the tumor bulk, resulting
in diminished/lower luciferin concentrations into the
central zone of the tumor [5].
Overall survival is the most important endpoint to
determine the efficacy of an anticancer treatment. In
Fig. 1 An example of a C57BL/6 J-Tyrc-2J/J mouse with ascites.
Mouse inoculated with 10 × 106 ID8-fLuc cells. Weight 32 g with
appreciable ascites
Fig. 2 Weight curves and BLI signal of mice inoculated
intraperitoneal with ID8-fLuc cells. a Weight curves of mice inoculated
intraperitoneal with either 10 × 106 or 15 × 106 ID8-fLuc cells. Relative
weight to weight at inoculation is used. When inoculating 15 × 106
ID8-fLuc cells, ascites is clinically appreciable 6 weeks after inoculation,
compared to 8 weeks after inoculation in the 10 × 106 ID8-fLuc
cells group. b BLI-signal of the animals described in 2A, weekly
measurements in photons per second (p/s). Using pieceweise
multilevel model we can show a statistical difference between
the two groups up to week 6, when ascites arises in the 15 ×
106 ID8-fLuc group. c BLI results of mice with important ascites
scanned without intervention or after drainage of ascites. We see
a clear increase in the BLI signal after drainage of ascites. This is
statistically significant using paired t-test. These results show that
the presence of ascites decreases the BLI signal
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animal models the strength of survival data depends
on the criteria for euthanasia. In the study of Liao et
al. clinical signs of disease or distress, interference of
the tumor with normal bodily functions and develop-
ment of ascites are used as end points. These criteria
are vague and inter-observer variability is problematic.
Moreover, the presence of ascites cannot be used as
an end point. Ascites is a sign of widespread disease,
but can be treated. Patients will in those cases
undergo ascites drainage and/or initiation of chemo-
therapy. In an effort to mimic the clinical process as
close as possible in our animal model set-up, we
therefore decided to drain ascites in mice once they
reached 32 g. Figure 3a shows an overview of the
weight evolution in our experimental groups and the
effect of draining ascites on the overall weight and sur-
vival. We could drain up to 12 mL (in average 8.81 mL
±2.97 mL) per treatment. Repetitive draining of asci-
tes (up to 5 times) resulted in a significantly im-
proved median survival from 63.5 to 73 days
(Fig. 3b). We therefore conclude that ascites is not a
good criterion for euthanasia to determine overall
survival. As an alternative, we propose in Table 1 an
overview of the euthanasia criteria we apply in our
ID8-Fluc mouse model for ovarian cancer. These im-
proved criteria provide more reproducible guidelines
for the euthanasia of animals with ovarian cancer,
without renouncing clinical relevance.
The authors spent a lot of effort in studying the
changes in the humoral and cellular immunity due to
the Luciferase insert. This is highly valuable informa-
tion, especially for the use of the model in immuno-
therapy research. It is reassuring to see that although
serum Luciferase IgG increases, it does not seem to
have a detrimental influence on tumor growth repre-
sented by the BLI-signal. After transfection these cells
express not only firefly Luciferase, but also the resist-
ance protein (e.g., Puromycin resistance protein) on
which they are selected. This protein is also a possible
source of immunogenicity of the tumor. However, we
would like to point out that in our model we noticed
an increase in the in vivo tumor growth after stable len-
tiviral transduction and selection compared to the par-
ental wild type ID8 (ID8-WT) model. As depicted in
Fig. 4, onset of weight gain due to ascites occurs around
day 65 after inoculation with 5 × 106 ID8-fLuc cells,
whereas this in only the case in 25 % of mice injected
with ID8-WT (n = 1 out of 4 mice) at day 80. This
suggests that there is no improved immune control of
tumor growth in the transfected cell line, on the con-
trary, if anything the ID8-fLuc cell line grows faster
in vivo when compared to the parental cell line.
In the article of Liao et al. FACS analysis was per-
formed on ascites, spleen and tumor of ID8-WT in-
oculated mice compared to ID8-Luc2 inoculated mice
at 12 to 15 weeks after inoculation to evaluate the
Fig. 3 Ascites drainages in the ID8-fluc ovarian cancer mouse model.
a Weight curves of mice inoculated intraperitoneal with 10 × 106
ID8-fLuc cells. Absolute weights of individual animals are depicted.
Results of two pooled experiments. b Kaplan-Meier curve showing
survival of 10 mice inoculated with 10 × 106 ID8-fLuc as shown in a.
The black curve depicts survival when draining the ascites and
using our improved euthanasia criteria. The grey curve depicts
survival when using the criteria described by Liao et al. Repetitive
drainages of ascites lead to a significantly (p = 0,001) prolonged
survival (Mantel-Cox)
Table 1 Improved euthanasia criteria
Criteria of
euthanasia
Liao et al. Improved criteria
Weight Cachexia Loss of 2 g in 48 h







Anorexia Hunched back with tremor
Ascites /
/ No spontaneous movement
when nudged
Weight and clinical status should be evaluated once every 48 h. The improved
criteria allow for more objective criteria for euthanasia of animals
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tumor microenvironment. These are late stage mice
in which immunosuppression has completely taken
over from immune control. These results prove that
in late stage animals there is no difference in the
microenvironment due to the expression of luc2, but
do not allow us to draw conclusions concerning early
disease, when there is still an equilibrium between
immune control and immune escape. Furthermore to
determine the change in in vivo tumor growth due to
the Luciferase insert, it would be more relevant to
flank the firefly Luciferase cDNA with loxP sites,
allowing Cre mediated excision of the cassette once
the stable cell line is established, providing a perfect
control. When comparing the cell line with and with-
out the addition of Cre recombinase, the only differ-
ence is the presence firefly Luciferase and not the
selection pressure that has been put on the cells dur-
ing the transfection and selection process.
Conclusion
In conclusion, the use of codon-optimized firefly lucifer-
ase Luc2 expressed in ID8 cells as described by Liao et
al. is suitable for the evaluation of tumor load in early
stage disease. Care should be taken in the interpretation
of BLI results once ascites occurs. When using overall
survival as an outcome measure in this model we rec-
ommend repeated ascites drainages to avoid underesti-
mating survival. The use of orthotopic, immune
competent models for ovarian cancer should be encour-
aged, as they are an adequate representation of the clinical
setting of ovarian cancer patients.
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